Dec 12 |
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
|
Dec 11 |
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
|
Nov 30 |
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
|
Nov 28 |
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
|
Nov 23 |
Connect and Simcere sign license agreement for autoimmune drug Rademikibart
|
Nov 21 |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
|
Nov 21 |
Connect Biopharma stock rises on positive data from dermatitis mAb
|
Nov 21 |
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
|
Nov 21 |
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
|
Nov 20 |
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
|